Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA panel conflicts of interest

This article was originally published in The Gray Sheet

Executive Summary

Reconciled FY 2006 FDA appropriations bill passes the House Oct. 28 with a "very watered-down" version of an advisory committee conflict-of-interest (CoI) provision, according to Rep. Maurice Hinchey (D-N.Y.), who succeeded in adding a CoI amendment to the original House bill in June. The final language requires that panel member conflicts of interest and waivers for conflicts be posted on FDA's website at least 15 days prior to a meeting or as soon as possible if the conflict is identified closer to the meeting date. Hinchey's amendment would have prohibited FDA from granting CoI waivers (1"The Gray Sheet" June 13, 2005, In Brief)...

Related Content

As FDA Posts Waivers, House Okays Bill To Ban Panel Members With Conflicts
FDA budget
Senate passes approps
CDRH funded in full



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts